Europe Biomarker Technologies Market, By Test Type (Solid Biopsy, Liquid Biopsy), By Technology (Immunoassay, DDPCR, Next Generation Sequencing (NGS), Mass Spectrometry, DHPLC, Others), By Product (Consumables, Instruments, Services, Software/Informatics), By Indication (Oncology, Infectious Diseases, Autoimmune Disorders, Cardiovascular Disorders, Others), By End User (Pharmaceutical Companies, Hospitals, CROs, Diagnostic Labs, Research Institutes), By Application (Clinical Diagnostics, Research, Drug Discovery & Development), By Country, Forecast & Opportunities, 2028

December 2022 | 85 pages | ID: E57924B9B70FEN
TechSci Research

Abstracts

Europe biomarker technologies market is expected to observe impressive growth during the forecast period, 2024-2028. Widespread incidences of various diseases such as cancer, diabetes, cardiovascular and neurological disorders, among others coupled with the growing technological advancements are expected to bolster the growth of the Europe biomarker technologies market. According to the IDF Diabetes Atlas, in 2021, about 61 million adults aged from 20 to 79 years were living with diabetes in the Europe. Besides, Europe has the highest number of children and adolescents with type 1 diabetes, accounting for 295,000 in total. Biomarker technologies are reliable and cost-effective which are used for diagnosis, drug development, and formulation. They are widely used for the early diagnosis of several diseases and disorders. The other factors supporting the market’s growth are rising number of individuals who are suffering from cancer, robust growth of the geriatric population, increase in healthcare expenditure, escalating demand for early and effective diagnosis, rising awareness about the early detection of cancer for better treatment, increasing investments in R&Ds in order to develop technologically advanced products, growing clinical trials for biomarker, and rising involvement from private sector and government. Additionally, governments across various European nations are also promoting biomarker technologies by increasing funding for biomarker research. Thus, increasing R&D activities is further expected to propel the growth of Europe biomarker technologies market in coming years. Moreover, growing adoption of biomarker technologies in drug development and genome mapping programs and increasing preference for personalized medicines is acting as major growth driver for Europe biomarker technologies market.

Europe biomarker technologies market is segmented into test type, technology, product, indication, end user, application, and country. Based on indication, the market can be segmented into oncology, infectious diseases, autoimmune disorders, cardiovascular disorders and others. Among them, the cardiovascular disorders segment is expected to undergo fastest CAGR during the forecast period owing to rise in number of people suffering from cardiovascular diseases.

Based on application, Europe biomarker technologies market is segmented into clinical diagnostics, research and drug discovery & development. Among these, the drug discovery segment is expected to witness significant growth through 2028 as biomarker technologies are helpful in drug discovery particularly for cancer and cardiovascular diseases.

Major players operating in the Europe biomarker technologies market are F. Hoffmann-La Roche AG, Merck KGAA, Beckman Coulter, Inc., Qiagen N.V., Biom?rieux SA, Bio-Rad Laboratories N.V., Siemens AG, Abbott Molecular Inc., Danaher Corporation, and Epigenomics AG. The companies are undergoing growth strategies such as mergers & acquisitions and product innovation.

Objective of the Study:

• To analyze and estimate the market size of Europe biomarker technologies market from 2018 to 2021.
• To estimate and forecast the market size of Europe biomarker technologies market from 2022 to 2028 and growth rate until 2028.
• To classify and forecast Europe biomarker technologies market based on test type, technology, product, indication, end user, application, company, and country.
• To identify dominant country or segment in the Europe biomarker technologies market.
• To identify drivers and challenges for Europe biomarker technologies market.
• To examine competitive developments such as expansions, mergers & acquisitions, etc., in Europe biomarker technologies market.
• To identify and analyze the profile of leading players operating in Europe biomarker technologies market.
• To identify key sustainable strategies adopted by market players in Europe biomarker technologies market.

TechSci Research performed both primary as well as exhaustive secondary research for this study. Initially, TechSci Research sourced a list of biomarker technologies companies across Europe. Subsequently, TechSci Research conducted primary research surveys with the identified companies. While interviewing, the respondents were also enquired about their competitors. Through this technique, TechSci Research could include the companies who could not be identified due to the limitations of secondary research. TechSci Research analyzed the presence of all major players across Europe.

TechSci Research calculated the market size of Europe biomarker technologies market using a bottom-up approach, wherein data for various end-user segments was recorded and forecast for the future years. TechSci Research sourced these values from the industry experts and company representatives and externally validated through analyzing historical data of these services and end users for getting an appropriate, overall market size. Various secondary sources such as company websites, news articles, press releases, company annual reports, investor presentations and financial reports were also studied by TechSci Research.

Key Target Audience:

• Biomarker technology companies, vendors, end users and other stakeholders
• Government bodies such as regulating authorities and policy makers
• Organizations, forums, and alliances related to biomarker technologies
• Market research and consulting firms

The study is useful in providing answers to several critical questions that are important for the industry stakeholders such as biomarker technology companies, vendors, end users, etc., besides allowing them in strategizing investments and capitalizing on market opportunities.

Report Scope:

In this report, Europe biomarker technologies market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

• Europe Biomarker Technologies Market, By Test Type:
• Solid Biopsy
• Liquid Biopsy
• Europe Biomarker Technologies Market, By Technology:
• Immunoassay
• DDPCR
• Next Generation Sequencing (NGS)
• Mass Spectrometry
• DHPLC
• Others
• Europe Biomarker Technologies Market, By Product:
• Consumables
• Instruments
• Services
• Software/Informatics
• Europe Biomarker Technologies Market, By Indication:
• Oncology
• Infectious Diseases
• Autoimmune Disorders
• Cardiovascular Disorders
• Others
• Europe Biomarker Technologies Market, By End User:
• Pharmaceutical Companies
• Hospitals
• CROs
• Diagnostic Labs
• Research Institutes
• Europe Biomarker Technologies Market, By Application:
• Clinical Diagnostics
• Research
• Drug Discovery & Development
• Europe Biomarker Technologies Market, By Country:
• Italy
• France
• United Kingdom
• Germany
• Spain
• Belgium
• Netherlands

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in Europe biomarker technologies market.

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company’s specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Profit Margin Analysis

• Profit margin analysis in case of direct and indirect sales channel.

Contents

1. PRODUCT OVERVIEW

1.1. Market Definition
1.2. Scope of the Market
  1.2.1. Markets Covered
  1.2.2. Years Considered for Study
  1.2.3. Key Market Segmentations

2. RESEARCH METHODOLOGY

2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations

3. EXECUTIVE SUMMARY

3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends

4. VOICE OF CUSTOMER

5. CLINICAL TRIAL ANALYSIS

5.1. Ongoing Clinical Trials
5.2. Completed Clinical Trials
5.3. Terminated Clinical Trials
5.4. Breakdown of Pipeline, By Development Phase
5.5. Breakdown of Pipeline, By Status
5.6. Breakdown of Pipeline, By Study Type
5.7. Breakdown of Pipeline, By Country
5.8. Clinical Trials Heat Map

6. EUROPE BIOMARKER TECHNOLOGIES MARKET OUTLOOK

6.1. Market Size & Forecast
  6.1.1. By Value
6.2. Market Share & Forecast
  6.2.1. By Test Type (Solid Biopsy, Liquid Biopsy)
  6.2.2. By Technology (Immunoassay, DDPCR, Next Generation Sequencing (NGS), Mass Spectrometry, DHPLC, Others)
  6.2.3. By Product (Consumables, Instruments, Services, Software/Informatics)
  6.2.4. By Indication (Oncology, Infectious Diseases, Autoimmune Disorders, Cardiovascular Disorders, Others)
  6.2.5. By End User (Pharmaceutical Companies, Hospitals, CROs, Diagnostic Labs, Research Institutes)
  6.2.6. By Application (Clinical Diagnostics, Research, Drug Discovery & Development)
  6.2.7. By Company (2022)
  6.2.8. By Country
6.3. Market Map

7. FRANCE BIOMARKER TECHNOLOGIES MARKET OUTLOOK

7.1. Market Size & Forecast
  7.1.1. By Value
7.2. Market Share & Forecast
  7.2.1. By Test Type
  7.2.2. By Technology
  7.2.3. By Product
  7.2.4. By Application

8. GERMANY BIOMARKER TECHNOLOGIES MARKET OUTLOOK

8.1. Market Size & Forecast
  8.1.1. By Value
8.2. Market Share & Forecast
  8.2.1. By Test Type
  8.2.2. By Technology
  8.2.3. By Product
  8.2.4. By Application

9. UNITED KINGDOM BIOMARKER TECHNOLOGIES MARKET OUTLOOK

9.1. Market Size & Forecast
  9.1.1. By Value
9.2. Market Share & Forecast
  9.2.1. By Test Type
  9.2.2. By Technology
  9.2.3. By Product
  9.2.4. By Application

10. ITALY BIOMARKER TECHNOLOGIES MARKET OUTLOOK

10.1. Market Size & Forecast
  10.1.1. By Value
10.2. Market Share & Forecast
  10.2.1. By Test Type
  10.2.2. By Technology
  10.2.3. By Product
  10.2.4. By Application

11. SPAIN BIOMARKER TECHNOLOGIES MARKET OUTLOOK

11.1. Market Size & Forecast
  11.1.1. By Value
11.2. Market Share & Forecast
  11.2.1. By Test Type
  11.2.2. By Technology
  11.2.3. By Product
  11.2.4. By Application

12. FINLAND BIOMARKER TECHNOLOGIES MARKET OUTLOOK

12.1. Market Size & Forecast
  12.1.1. By Value
12.2. Market Share & Forecast
  12.2.1. By Test Type
  12.2.2. By Technology
  12.2.3. By Product
  12.2.4. By Application

13. GREECE BIOMARKER TECHNOLOGIES MARKET OUTLOOK

13.1. Market Size & Forecast
  13.1.1. By Value
13.2. Market Share & Forecast
  13.2.1. By Test Type
  13.2.2. By Technology
  13.2.3. By Product
  13.2.4. By Application

14. PORTUGAL BIOMARKER TECHNOLOGIES MARKET OUTLOOK

14.1. Market Size & Forecast
  14.1.1. By Value
14.2. Market Share & Forecast
  14.2.1. By Test Type
  14.2.2. By Technology
  14.2.3. By Product
  14.2.4. By Application

15. BULGARIA BIOMARKER TECHNOLOGIES MARKET OUTLOOK

15.1. Market Size & Forecast
  15.1.1. By Value
15.2. Market Share & Forecast
  15.2.1. By Test Type
  15.2.2. By Technology
  15.2.3. By Product
  15.2.4. By Application

16. CROATIA BIOMARKER TECHNOLOGIES MARKET OUTLOOK

16.1. Market Size & Forecast
  16.1.1. By Value
16.2. Market Share & Forecast
  16.2.1. By Test Type
  16.2.2. By Technology
  16.2.3. By Product
  16.2.4. By Application

17. MARKET DYNAMICS

17.1. Drivers
17.2. Challenges

18. MARKET TRENDS & DEVELOPMENTS

19. COMPETITIVE LANDSCAPE

19.1. Competition Outlook
19.2. Regional Players Profiled (Leading Companies)
  19.2.1. F. Hoffmann-La Roche AG
  19.2.2. Merck KGAA
  19.2.3. Beckman Coulter, Inc.
  19.2.4. Qiagen N.V.
  19.2.5. Biom?rieux SA
  19.2.6. Bio-Rad Laboratories N.V.
  19.2.7. Siemens AG
  19.2.8. Abbott Molecular Inc.
  19.2.9. Danaher Corporation
  19.2.10. Epigenomics AG

20. STRATEGIC RECOMMENDATIONS

(Note: The companies list can be customized based on the client requirements.)